Showing results (11-20 of 53) with videos related to
Sort By:
Pageof 6
Journal of Clinical Pharmacology|April 12, 2017
Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple SclerosisKumar Kandadi Muralidharan, Geoffrey Kuesters, Tatiana Plavina, et al.Cephalalgia : an International Journal of Headache|November 24, 2020
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine preventionMessoud Ashina, David Doležil, Jo H Bonner, et al.CNS Drugs|May 8, 2019
Correction to: A Multi‑Center, Open‑Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy FemalesYang Xu, Kristin Gabriel, Yi Wang, et al.CNS Drugs|April 10, 2019
A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy FemalesYang Xu, Kristin Gabriel, Yi Wang, et al.Current Medical Research and Opinion|June 16, 2011
The changing face of multiple sclerosis clinical trial populationsBernard M J Uitdehaag, Frederik Barkhof, Patricia K Coyle, et al.Analytical Chemistry|April 25, 2008
High-throughput profiling of ion channel activity in primary human lymphocytesDaniel J Estes, Sohiel Memarsadeghi, Steven K Lundy, et al.Headache|October 16, 2019
A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese AdultsFumihiko Sakai, Takao Takeshima, Yoshihisa Tatsuoka, et al.Headache|June 21, 2021
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled studyTakao Takeshima, Fumihiko Sakai, Koichi Hirata, et al.Headache|March 25, 2021
Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraineFumihiko Sakai, Takao Takeshima, Yoshihisa Tatsuoka, et al.European Neurology|April 26, 2008
Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparisonMark S Freedman, Bruce Hughes, Daniel D Mikol, et al.Pageof 6